Mesa R&D Tax Credit Benefits for Companies

R&D Tax Credits for Mesa, Arizona Businesses

Mesa, Arizona, thrives in industries such as aerospace, healthcare, education, manufacturing, and tourism. Top companies in the city include Boeing, a leading aerospace manufacturer; Banner Health, a major healthcare provider; Mesa Public Schools, a large educational institution; MD Helicopters, a prominent aerospace company; and Mesa Gateway Airport, a key transportation hub. The R&D Tax Credit can help these industries reduce tax liabilities, promote innovation, and enhance business performance. By utilizing the R&D Tax Credit, companies can reinvest savings into advanced research driving growth and competitiveness in Mesa’s economy.

Find out more

Are you eligible?

Why choose us?

Pass an Audit?

Swanson Reed is one of the only companies in the United States to exclusively focus on R&D tax credit preparation. Swanson Reed’s office location at 3104 E Camelback Road, Phoenix, Arizona is less than 20 miles away from Mesa and provides R&D tax credit consulting and advisory services to Mesa and the surrounding areas such as: Phoenix, Tucson, Chandler, Gilbert and Glendale.

If you have any questions or need further assistance, please call or email our local Arizona Partner on (520) 336-9423.
Feel free to book a quick teleconference with one of our Arizona R&D tax credit specialists at a time that is convenient for you. Click here for more information about R&D tax credit management and implementation.

Schedule a Teleconference

Mesa, Arizona Patent of the Year – 2024/2025

Mirror Biologics Inc. has been awarded the 2024/2025 Patent of the Year for its groundbreaking immunotherapy innovation. Their invention, detailed in U.S. Patent No. 11883490, titled ‘Induction of IL-12 using immunotherapy’, employs activated allogeneic immune cells to safely induce interleukin-12 (IL-12) production, enhancing the body’s defense against cancer and infectious diseases.

This novel approach stimulates a Th1-type immune response, crucial for combating tumors and pathogens. By administering these activated cells, the therapy elevates IL-12 levels in patients’ plasma without the toxicity typically associated with direct IL-12 treatments. This advancement offers a safer, more effective method to boost the immune system’s natural defenses.

The technology is part of Mirror Biologics’ Mirror Effect® platform, which leverages the body’s own immune mechanisms to target diseases. Unlike traditional therapies requiring genetic modification or immunosuppression, this method uses non-genetically altered, off-the-shelf immune cells, simplifying treatment and reducing risks.

By harnessing the body’s innate ability to fight disease, Mirror Biologics’ innovation represents a significant step forward in immunotherapy. It holds promise for treating a range of conditions, including various cancers and infectious diseases, by enhancing the immune system’s capacity to respond effectively.